Monday, 3 September 2012

Cysview





Dosage Form: intravesical solution
FULL PRESCRIBING INFORMATION

Indications and Usage for Cysview


Cysview is an optical imaging agent indicated for use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. Cysview is used with the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system to perform cystoscopy with the blue light setting (Mode 2) as an adjunct to the white light setting (Mode 1).



Limitations of Use


Cysview is not:


  • a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer [see Warnings and Precautions (5.2)].

  • for repetitive use. The potential risks associated with repetitive exposure, including sensitization and adverse effects of blue light have not been evaluated [see Warnings and Precautions (5.1)].


Cysview Dosage and Administration



Recommended Dose


The recommended dose for adults is 50 mL of reconstituted solution of Cysview [see Dosage and Administration (2.2)], instilled into the bladder via a urinary catheter [see Dosage and Administration (2.3)].



Reconstitution of Cysview


Cysview is supplied as a kit containing two vials: a clear glass vial labeled as Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution, containing 100 mg hexaminolevulinate hydrochloride as a powder, and a vial labeled as DILUENT for Cysview, containing 50 mL of the diluent in a polypropylene vial.


Perform all steps under aseptic conditions. Use gloves during the reconstitution procedure; skin exposure to hexaminolevulinate hydrochloride may increase the risk for sensitization to the drug.


Use a 50 mL syringe with a Luer Lock tip throughout the reconstitution procedure to ensure that the correct concentration (2 mg/mL) of the drug is obtained and that a stable syringe-catheter connection is made for the bladder instillation of Cysview.



          Figure 1.


  1. Remove the cap from the sterile 50 mL syringe and carefully retain it for subsequent reattachment to the syringe (step 4). Attach a needle to the syringe and withdraw 50 mL of the diluent (Figure 1).

    Figure 2.

  2. Penetrate the stopper of the Cysview powder vial with the needle and inject 10 mL of the diluent from the syringe into the powder vial (Figure 2).

    Figure 3.

  3. Without withdrawing the needle from the vial, hold the powder vial and syringe in a firm grip (Figure 3) and gently shake to dissolve of the powder in the diluent. The powder normally dissolves almost immediately.

    Figure 4.

  4. Withdraw all of the dissolved solution from the powder vial (10 mL) into the 50 mL syringe (Figure 4).

    Figure 5.

  5. Remove the needle from the powder vial, disconnect the needle from the syringe tip and discard it. Plug the syringe with the syringe cap (Figure 5). Gently mix the contents of the syringe. The reconstituted solution of Cysview is colorless to pale yellow and clear to slightly opalescent, and free from visible particles.

    Figure 6.

  6. Peel off the detachable portion of the label (starting at the corner marked with a black triangle) from the Cysview powder vial and affix it to the syringe containing the solution of Cysview (Figure 6). Add two hours to the present time and write the resulting expiration time and date on the syringe label.

Cysview is now reconstituted and ready for use. Instill the reconstituted solution of Cysview into the bladder. If unable to administer the solution shortly after reconstitution, the solution may be stored for up to 2 hours in a refrigerator at 2°-8°C (36°- 46°F) in the labeled syringe. If not used within 2 hours, discard the solution. [see Dosage and Administration (2.2) and How Supplied/Storage and Handling (16)]



Bladder Instillation of Cysview


For bladder instillation of the solution of Cysview, use straight, or intermittent, urethral catheters with a proximal funnel opening that will accommodate the Luer Lock adapter. Use only catheters made of vinyl (uncoated or coated with hydrogel), latex (amber or red), and silicone to instill the reconstituted Cysview. Do not use catheters coated or embedded with silver or antibiotics. In-dwelling bladder catheters (Foley catheters) may be used if the catheters are inserted shortly prior to Cysview administration and are removed following the Cysview instillation.


Use the following steps for bladder instillation of Cysview:


  1. Using standard sterile catheterization technique, first insert the urethral catheter into the bladder of the patient and use the catheter to completely empty the patient's bladder before instillation of Cysview.

    Figure 7.

  2. To attach the syringe containing the solution of Cysview to the catheter, do the following:
    • Remove the syringe cap from the 50 mL syringe that contains the solution of Cysview.

    • Attach the Luer Lock end of the (provided) catheter adapter to the syringe.

    • Insert the tapered end of the catheter adapter into the funnel opening of the catheter. See Figure 7, with the connection enlarged in the inset.


  3. Slowly instill the solution of Cysview into the bladder through the catheter (Figure 7), ensuring that the complete volume of the syringe (50 mL) is administered.

  4. After the solution is instilled, remove the catheter and instruct the patient to retain the solution within the bladder for at least 1 hour; do not exceed 3 hours [see Dosage and Administration (2.4)]. Patients may stand, sit and move about during the time period between instillation and start of the cystoscopic procedure.

  5. Evacuate the solution of Cysview from the bladder as part of routine emptying of the bladder immediately prior to the initiation of the cystoscopic procedure (refer to the Karl Storz PDD Telescope Instruction manual). Also, the patient may void and completely empty the bladder prior to the procedure.

Avoid skin contact with Cysview. If skin does come in contact with Cysview, wash immediately with soap and water and dry off. After voiding the bladder of Cysview, routinely wash the patient's perineal skin region with soap and water and dry.



Use of the Karl Storz D-Light C Photodynamic Diagnostic (PDD) System


Cysview imaging requires the use of the Karl Storz D-Light C PDD system, which consists of a light source, a camera and a telescope. The light source enables both white light cystoscopy and blue light (wavelength 360 – 450 nm) fluorescence cystoscopy. Familiarity with this system is essential before beginning the procedure and before instilling Cysview into the bladder. For system set up and general information for the safe use of the PDD system, refer to the Karl Storz instruction manual for the PDD system and the instruction manuals for each of the system components. The PDD System is not for use by healthcare providers with green-red color blindness.



Cystoscopic Examination



Training


Training and proficiency in cystoscopic procedures are essential prior to the use of Cysview. Carefully review the instruction manuals provided with the Karl Storz D-Light C Photodynamic Diagnosis (PDD) System. For additional training in the use of the PDD System, contact the manufacturer's representative.



Preparation for Cystoscopy


Initiate the cystoscopic examination within 30 minutes after evacuation of Cysview from the bladder, but no less than 1 or more than 3 hours after Cysview is instilled in the bladder. If the patient did not retain Cysview in the bladder for 1 hour, allow 1 hour to pass from the instillation of Cysview into the bladder to the start of the cystoscopic examination. The efficacy of Cysview has not been established when the solution was retained for less than 1 hour.



Cystoscopic Examination


Empty the patient's bladder and then fill the bladder with a clear fluid (standard bladder irrigation fluid) in order to distend the bladder wall for cystoscopic visibility. Ensure adequate irrigation during examination of the bladder; blood, urine or floating particles in the bladder may interfere with visualization under both white light and blue light.


First perform a complete cystoscopic examination of the entire bladder under white light (Mode 1) and then repeat the examination of the entire bladder surface under blue light (Mode 2) unless the white light cystoscopy reveals extensive mucosal inflammation. Do not perform the blue light cystoscopy if the white light cystoscopy reveals wide-spread mucosal inflammation. Abnormalities of the bladder mucosa during blue light cystoscopy are characterized by the detection of red, homogenous and intense fluorescence. The margins of the abnormal lesions are typically well-demarcated and in contrast to the normal urothelium, which appears blue. Register and document (map) the location and appearance (e.g. papillary) of suspicious lesions and abnormalities seen under either white or blue light.


During the cystoscopic examination, be aware that:


  • a red fluorescence is expected at the bladder outlet and the prostatic urethra; this fluorescence occurs in normal tissue and is usually less intense and more diffuse than the bladder mucosal fluorescence associated with malignant lesions.

  • tangential light may give false fluorescence. To help avoid false fluorescence, hold the endoscope perpendicular and close to the bladder wall with the bladder distended.

  • false positive fluorescence may result from scope trauma from a previous cystoscopic examination and/or bladder inflammation [see Warnings and Precautions (5.3)].

  • malignant lesions may not fluoresce following Cysview administration, particularly if the lesions are coated with necrotic tissue. Blue light may fail to detect T2 tumors which have a tendency to be necrotic on the surface, and necrotic cells generally do not fluoresce [see Warnings and Precautions (5.3)].

  • when performing the blue light cystocopy, avoid prolonged blue light exposure. Studies have not evaluated the potential for adverse effects from blue light. In the controlled clinical trial, the cumulative blue light exposure from bladder mapping did not exceed 12 minutes and checking for complete tumor resection under blue light did not exceed 8 minutes for any patient [see Clinical Studies (14)].

Perform biopsy and/or resection of suspicious lesions by transurethral resection of the bladder (TURB) only after completing white and blue light cystoscopic examinations with bladder mapping. Using standard cystoscopic practices, obtain biopsies of abnormal areas identified during either white or blue light examination and perform resections. Always check for the completeness of the resections under both white light and blue light before finalizing the TURB procedure.



Dosage Forms and Strengths


Cysview (hexaminolevulinate hydrochloride) is supplied as a kit containing:


  • Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution, 100 mg, as a powder in a 10 mL clear glass vial.

  • DILUENT for Cysview, 50 mL, in a polypropylene vial.

  • One Luer Lock catheter adapter (to connect the syringe containing the reconstituted solution of Cysview to the urethral catheter for bladder instillation of Cysview).

Once reconstituted, the solution of Cysview contains 2 mg/mL of hexaminolevulinate hydrochloride.



Contraindications


Cysview is contraindicated in patients with:


  • porphyria

  • gross hematuria

  • BCG immunotherapy or intravesical chemotherapy within the past 90 days

  • known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid


Warnings and Precautions



Anaphylaxis


Anaphylaxis, including anaphylactoid shock, has been reported following administration of Cysview [see Adverse Reactions (6.2)]. Prior to and during use of the Cysview, have trained personnel and therapies available for the treatment of anaphylaxis. The safety of repetitive Cysview exposures has not been evaluated.



Failed Detection


Cysview may fail to detect some bladder tumors, including malignant lesions. Cysview is not a replacement for random biopsies or any other procedure usually performed in the cystoscopic evaluation for cancer. In the controlled clinical trial, Cysview failed to detect 10% of lesions confirmed as malignant within the study drug group [see Clinical Studies (14)]. Do not perform cystoscopy with blue light alone as malignant lesions can be missed unless the bladder is initially examined under white light [see Dosage and Administration (2.5)].



False Fluorescence


Fluorescent areas detected during blue light cystoscopy may not indicate a bladder mucosal lesion. In the controlled clinical study, biopsies from one of every four fluorescent areas showed neither dysplasia nor carcinoma, if the areas were not also identified during white light cystoscopy [see Clinical Studies (14)]. In addition to these false detections, fluorescent areas within the bladder mucosa may result from inflammation, cystoscopic trauma, scar tissue or bladder mucosal biopsy from a previous cystoscopic examination.


The presence of urine and/or blood within the bladder may interfere with the detection of tissue fluorescence. To enhance the diagnostic utility of Cysview with the Karl Storz D-Light C PDD System:


  • ensure the bladder is emptied of urine prior to the instillation of fluids at cystoscopy;

  • biopsy/resect bladder mucosal lesions only following completion of both white light and blue light cystoscopy;


Adverse Reactions


Anaphylaxis has been reported following exposure to Cysview [see Warnings and Precautions (5.1)].



Clinical Study Experience


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.


In six clinical trials, safety data were obtained from 1,324 patients, aged 32 to 96 years with a median age of 69 years, all primarily Caucasian and approximately 75% male. All patients were evaluated after a single instillation of 50 mL solution of Cysview. Of these patients, 161 (12.2%) patients reported at least one adverse reaction. The most common adverse reaction was bladder spasm (reported in 2.2% of the patients) followed by dysuria, hematuria, and bladder pain. No patients experienced anaphylaxis. In the controlled clinical study, adverse reactions were similar in nature and rate between the study drug group and the control group [see Clinical Studies (14)].



Postmarketing Experience


Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.


Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis and abnormal urinalysis have been reported during post marketing use of Cysview.



Drug Interactions


No specific drug interaction studies have been performed.



USE IN SPECIFIC POPULATIONS



Pregnancy



Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Cysview should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.



Nursing Mothers


It is not known whether hexaminolevulinate is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when Cysview is administered to nursing mothers.



Pediatric Use


Safety and effectiveness in pediatric patients have not been established.



Geriatric Use


Of 1823 subjects in clinical studies of Cysview, 67% were 65 years and over while 34% were 75 years and over. No clinically important differences in safety or efficacy have been observed between older and younger patients in the controlled study.



Overdosage


No adverse events were reported in a dose-finding study conducted among patients whose bladders were instilled with twice the recommended concentration (dose) of solution of Cysview.



Cysview Description


Cysview contains hexaminolevulinate hydrochloride, an optical imaging drug that in solution form is instilled intravesically for use with photodynamic blue light cystoscopy as an adjunct to white light cystoscopy.


The chemical formula for hexaminolevulinate hydrochloride is C11H21NO3•HCl. Its molecular weight is 251.76 and it has the following structural formula:



Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution is intended for intravesical administration only after reconstitution with the supplied 50 mL DILUENT. Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution and DILUENT for Cysview are supplied together as a kit.


Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution is supplied as a sterile, non-pyrogenic, freeze-dried, white to off-white or pale yellow, powder containing 100 mg of hexaminolevulinate hydrochloride (equivalent of 85 mg of hexaminolevulinate) in a 10 mL clear glass vials. The DILUENT for Cysview is a sterile, non-pyrogenic solution (pH 6) containing 0.61 mg/mL disodium hydrogen phosphate, 0.58 mg/mL of potassium dihydrogen phosphate, 7.02 mg/mL of sodium chloride, hydrochloric acid, sodium hydroxide, and water for injection. It is a clear, colorless solution, free from visible particles, and is provided in a 50 mL polypropylene vial.


The reconstituted solution of Cysview contains 2 mg/mL of hexaminolevulinate hydrochloride and is colorless to pale yellow. It is free from visible particles and has a pH between 5.7 and 6.2.



Cysview - Clinical Pharmacology



Mechanism of Action


Cysview is an ester of the heme precursor, aminolevulinic acid. After bladder instillation, Cysview enters the bladder mucosa and is proposed to enter the intracellular space of mucosal cells where it is used as a precursor in the formation of the photoactive intermediate protoporphyrin IX (PpIX) and other photoactive porphyrins (PAPs). PpIX and PAPs are reported to accumulate preferentially in neoplastic cells as compared to normal urothelium, partly due to altered enzymatic activity in the neoplastic cells. After excitation with light at wavelengths between 360 and 450 nm, PpIX and other PAPs return to a lower energy level by fluorescing, which can be detected and used for cystoscopic detection of lesions. The fluorescence from tumor tissue appears bright red and demarcated, whereas the background normal tissue appears dark blue. Similar processes may occur in inflamed cells.



Pharmacodynamics


In vitro studies have shown increased porphyrin fluorescence in normal urothelium after exposure to Cysview. In the human bladder, a greater accumulation of porphyrins is proposed in neoplastic or inflamed cells, compared to normal urothelium. After bladder instillation of Cysview for approximately 1 hour and subsequent illumination with blue light at wavelengths 360 – 450 nm, the porphyrins will fluoresce red [see Dosage and Administration (2.5)].



Pharmacokinetics


After bladder instillation of [14C]-labeled Cysview (100 mg) for approximately 1 hour in healthy volunteers, absolute bioavailability of Cysview was 7% (90% confidence interval [CI]: 5%-10%). The [14C]-labeled substance(s) showed biphasic elimination, with an initial elimination half-life of 39 minutes, followed by a terminal half-life of approximately 76 hours. Whole blood analysis showed no evidence of significant binding of Cysview to erythrocytes. An in vitro study showed that Cysview underwent rapid metabolism in human blood.



Nonclinical Toxicology



Carcinogenesis, Mutagenesis, Impairment of Fertility


No studies in animals have been conducted to evaluate the carcinogenic potential of hexaminolevulinate hydrochloride.


Hexaminolevulinate hydrochloride was not mutagenic in in vitro reverse mutation tests in bacteria, or in chromosome aberration tests in human peripheral blood lymphocytes, and was negative in an in vivo micronucleus test in mice after intravenous injection of doses up to 45 mg/kg in the absence of light activation. Adequate studies have not been performed to evaluate the genetic toxicity of hexaminolevulinate hydrochloride in the presence of light activation.


Adequate reproductive and developmental toxicity studies in animals have not been performed to evaluate the effects of hexaminolevulinate hydrochloride on fertility.



Animal Toxicology and/or Pharmacology


Dose dependent neurological effects such as tremor, increased motor activity, and increased startle and touch escape responses were observed immediately after dosing at doses ≥ 30 mg/kg (24 times human systemic exposure based on the body surface area, using 10% as the upper level of 90% confidence interval of bioavailability) in a single dose rat study. The animals recovered to normal status by 60 min after dosing. Adverse neurological effects were also noted in other single or repeat dose toxicity studies.


Hexaminolevulinate hydrochloride had moderate to strong potential to cause skin sensitization based on a local lymph node assay in mouse.



Clinical Studies


The safety and efficacy of Cysview when used with photodynamic cystoscopy were studied in a prospective, multicenter, controlled clinical trial. Adult patients with known or suspected bladder cancer were randomized to either white light (WL) cystoscopy (control group, n = 384) or WL followed by blue light (BL) cystoscopy (study drug group, n = 395). Only the study drug group patients received Cysview by bladder instillation prior to cystoscopy. After bladder evacuation of Cysview, bladder lesion mapping was performed initially using the Karl Storz PDD system in the WL mode followed by lesion mapping in the BL mode. Control group patients underwent only WL cystoscopy with lesion mapping. The average age of the randomized patients was 69 years (range 24 to 96); 78% were male and 94% were Caucasian. All patients had previously undergone cystoscopy.


The main diagnostic efficacy outcome was assessed within the study drug group. This assessment compared lesions detected during an initial cystoscopic examination to their centralized histologic findings (the standard of truth). Following the initial diagnostic cystoscopy, patients within both study groups who had histologically confirmed Ta and/or T1 lesions underwent follow-up WL cystoscopy at 3, 6 and 9 months; these histologic evaluations were based upon the site assessments at both the initial and follow-up cystoscopy.


Diagnostic efficacy assessed the number of patients within the study drug group who had at least one additional Ta or T1 bladder cancer detected only by BL; the proportion of these patients was compared to a proposed threshold proportion of 10%. Within the study drug group, 286 patients had at least one Ta and/or T1 lesion, including 47 patients who had at least one of the lesions detected only by BL (see Table 1).











Table 1: BL Cystoscopic Ta and/or T1 Lesion Detection within the Study Drug Group

*

exact test comparison of the proportion to a threshold value of 10%

Number of patients with any Ta and/or T1 lesion detected with either WL or BL286
Number (%) of patients with any Ta and/or T1 lesion detected only with BL47 (16%)
p-value*0.001

Some malignant lesions were detected only by WL or BL (see Table 2).
























Table 2: Bladder Tumor Detection within the Study Drug Group by WL and/or BL Cystoscopy
Number of lesionsDetected by Both WL & BLDetected by WL OnlyDetected by BL Only
CIS, n = 6633627
Ta, n = 5804725256
T1, n = 9576109
T2 – T4, n = 473881

Among the lesions detected only by BL, 23% were negative for any carcinoma-related pathology, including dysplasia. Among the lesions detected only by WL, 17% were negative for any carcinoma-related pathology, including dysplasia.



How Supplied/Storage and Handling


Cysview is supplied as a kit labeled Cysview (hexaminolevulinate hydrochloride) Kit for Intravesical Solution, 100 mg. The kit contains:


  • One vial of Cysview (hexaminolevulinate hydrochloride) for Intravesical Solution, 100 mg, as a powder in a 10 mL clear glass vial.

  • One vial of DILUENT for Cysview, 50 mL, in a polypropylene vial.

  • One Luer Lock catheter adapter (to connect the syringe containing Cysview solution to the urethral catheter during instillation of Cysview).

NDC 10511-3001-1



Storage


Store Cysview (hexaminolevulinate hydrochloride) Kit for Intravesical Solution at 20°-25°C (68°-77°F); excursions are permitted to 15°-30°C (59°-86°F). Do not use beyond the expiry date printed on the carton.


Use the solution of Cysview shortly after reconstitution. If unable to use within this time period, the reconstituted solution can be stored under refrigeration at 2°-8°C (36°-46°F) for up to 2 hours in the 50 mL labeled syringe.



Patient Counseling Information


Ask patients if they have:


  • a diagnosis or a family history of porphyria

  • allergy to aminolevulinic acid or prior exposure to Cysview

  • gross hematuria

  • had BCG immunotherapy or chemotherapy within the bladder.

Inform patients that Cysview should be retained in the bladder for 1 hour from instillation of Cysview to the start of the cystoscopic procedure. If the patient cannot hold Cysview for 1 hour, but needs to void and expel Cysview from the bladder, he or she may void and should then inform a health care professional [see Dosage and Administration (2)].



Distributed by

Photocure Inc.

Princeton, NJ 08540 U.S.A.


Packaged and Labeled by

Orifice Medical AB

Ystad, Sweden


Cysview is a trademark of Photocure ASA.


Photodynamic Diagnostic (PDD) system is a

trademark of Karl Storz Endoscopy-America, Inc.


Photocure and the Photocure logo are trademarks of Photocure ASA.

© 2011 Photocure ASA – All rights reserved.


PL01-05-01



PRINCIPAL DISPLAY PANEL - 100 mg Kit Carton


PHOTOCURE®


Rx ONLY


Sterile.

Single Use Containers.

Discard unused portion.


ONE KIT


NDC 10511-3001-1


Cysview®

(hexaminolevulinate HCl)

KIT for Intravesical Solution


100 mg


For Bladder Instillation Only after

Reconstitution


Each KIT contains:


 

1 vial Cysview®(hexaminolevulinate HCl) for

Intravesical Solution 100 mg

 

1 vial DILUENT for Cysview®

 

1 Luer Lock catheter adapter

Reconstitution with supplied DILUENT for Cysview®

required before use (see insert).
























Cysview 
hexaminolevulinate hydrochloride  kit






Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)10511-3001










Packaging
#NDCPackage DescriptionMultilevel Packaging
110511-3001-11 KIT In 1 VIAL, PATENT DELIVERY SYSTEMNone











QUANTITY OF PARTS
Part #Package QuantityTotal Product Quantity
Part 11 VIAL, GLASS  50 mL
Part 21 VIAL  50 mL



Part 1 of 2
Cysview 
hexaminolevulinate hydrochloride  injection, powder, lyophilized, for solution










Product Information
   
Route of AdministrationINTRAVESICALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
hexaminolevulinate hydrochloride (hexaminolevulinate)hexaminolevulinate hydrochloride100 mg  in 50 mL





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
150 mL In 1 VIAL, GLASSNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02255509/01/2010




Part 2 of 2
DILUENT FOR Cysview 
diluent  injection










Product Information
   
Route of AdministrationINTRAVESICALDEA Schedule    






Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
No Active Ingredients Found














Inactive Ingredients
Ingredient NameStrength
potassium phosphate, monobasic 
sodium chloride 
hydrochloric acid 
sodium hydroxide 
water 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
150 mL In 1 VIALNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02255509/01/2011











Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02255509/01/2011


Labeler - Photocure Inc. (006629060)









Establishment
NameAddressID/FEIOperations
Ben Venue Laboratories, Inc.004327953MANUFACTURE









Establishment
NameAddressID/FEIOperations
Fresenius Kabi Norge AS731170932MANUFACTURE









Establishment
NameAddressID/FEIOperations
Orifice Medical AB508917689LABEL, PACK
Revised: 12/2011Photocure Inc.

Saturday, 1 September 2012

Tetrahydrozoline Drops


Pronunciation: te-tra-hye-DROZ-oh-leen
Generic Name: Tetrahydrozoline
Brand Name: Examples include Eye Moisturizing Relief and Murine Tears


Tetrahydrozoline Drops are used for:

Temporarily relieving redness, burning, and irritation caused by dry eyes. It may also be used for other conditions as determined by your doctor.


Tetrahydrozoline Drops are an eye decongestant and lubricant. It works by constricting the blood vessels in the eye and coating the eye, which relieves redness and dryness.


Do NOT use Tetrahydrozoline Drops if:


  • you are allergic to any ingredient in Tetrahydrozoline Drops

  • you have taken furazolidone or a monoamine oxidase (MAO) inhibitor (eg, phenelzine) within the past 14 days

Contact your doctor or health care provider right away if any of these apply to you.



Before using Tetrahydrozoline Drops:


Some medical conditions may interact with Tetrahydrozoline Drops. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have glaucoma, high blood pressure, diabetes, heart problems, or thyroid problems, or you are taking medicine for high blood pressure

Some MEDICINES MAY INTERACT with Tetrahydrozoline Drops. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Tricyclic antidepressants (eg, amitriptyline) because they may decrease Tetrahydrozoline Drops's effectiveness

  • Cocaine, furazolidone, MAO inhibitors (eg, phenelzine), or tricyclic antidepressants (eg, amitriptyline) because they may increase the risk of Tetrahydrozoline Drops's side effects, such as headache, fever, and high blood pressure

  • Bromocriptine or cocaine because their actions and side effects may be increased by Tetrahydrozoline Drops

This may not be a complete list of all interactions that may occur. Ask your health care provider if Tetrahydrozoline Drops may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Tetrahydrozoline Drops:


Use Tetrahydrozoline Drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Tetrahydrozoline Drops are for use in the eye only. Avoid contact with the nose, mouth, or other mucous membranes.

  • To use Tetrahydrozoline Drops, first, wash your hands. Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eye for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.

  • To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including your eye. Keep the container tightly closed.

  • If you miss a dose of Tetrahydrozoline Drops and you are using it regularly, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.

Ask your health care provider any questions you may have about how to use Tetrahydrozoline Drops.



Important safety information:


  • Remove contact lenses before using Tetrahydrozoline Drops.

  • Do not use Tetrahydrozoline Drops if it becomes cloudy or changes color.

  • Contact your doctor if you experience changes in your vision, eye pain, irritation, soreness, or continued redness, or if your condition does not improve after 3 days.

  • Use Tetrahydrozoline Drops with caution in CHILDREN because they may be more sensitive to its effects.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant while taking Tetrahydrozoline Drops, discuss with your doctor the benefits and risks of using Tetrahydrozoline Drops during pregnancy. It is unknown if Tetrahydrozoline Drops are excreted in breast milk. If you are or will be breast-feeding while you are using Tetrahydrozoline Drops, check with your doctor or pharmacist to discuss the risks to your baby.


Possible side effects of Tetrahydrozoline Drops:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Blurred vision; minor stinging when the medicine is dropped into the eye.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); changes in vision; eye pain; worsening or persistent eye irritation or redness.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.



If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Tetrahydrozoline Drops may be harmful if swallowed, especially in children.


Proper storage of Tetrahydrozoline Drops:

Store Tetrahydrozoline Drops at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Tetrahydrozoline Drops out of the reach of children and away from pets.


General information:


  • If you have any questions about Tetrahydrozoline Drops, please talk with your doctor, pharmacist, or other health care provider.

  • Tetrahydrozoline Drops are to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Tetrahydrozoline Drops. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Tetrahydrozoline resources


  • Tetrahydrozoline Use in Pregnancy & Breastfeeding
  • Tetrahydrozoline Drug Interactions
  • Tetrahydrozoline Support Group
  • 1 Review for Tetrahydrozoline - Add your own review/rating


Compare Tetrahydrozoline with other medications


  • Eye Dryness/Redness

Friday, 31 August 2012

Isoface




Isoface may be available in the countries listed below.


Ingredient matches for Isoface



Isotretinoin

Isotretinoin is reported as an ingredient of Isoface in the following countries:


  • Brazil

  • Colombia

  • Ecuador

  • Mexico

  • Peru

  • Venezuela

International Drug Name Search

Thursday, 30 August 2012

Copper Mate





Dosage Form: FOR ANIMAL USE ONLY

Copper Mate Drug Facts Label


Active Ingredients: Cupric Sulfate, Zinc Sulfate, Citric Acid [Powder for use in solution]



Directions: It is recommended for use in a 1% to 3% solution strength (by weight) with immersion lasting between 5 and 20 minutes, once or twice daily, for a period of time as prescribed by your veterinarian.



Warnings:


  • Copper and Zinc can be toxic to sheep. Do not allow animals to eat or drink the Copper Mate powder or hoof bath solution.

  • Know the volume of the hoof bath and calculate the amount of Copper Mate carefully.

  • DO NOT OVER DOSE by using more Copper Mate than what is recommended by your veterinarian.


For External Use Only

Keep out of reach of children.



Purpose:Copper Mate powder is used as an aid in hoof rot management under veterinary guidance.


Use:Copper Mate powder is used in hoof baths for cattle and sheep.



When Using this Product: By placing a clean water bath ahead of the treatment bath, animals will clean their hooves to some extent and keep the treatment bath clean longer. Hoof baths should only be part of an overall program that includes proper nutrition, regular hoof trimming, and hoof injury prevention.



Questions?: 1-800-567-7455 (24/7-Emergency Spill Line) or 1-905-878-8432



Copper Mate Bag Label




Copper Mate

HOOF TREATMENT

Contains a Proprietary Blend of Copper and Zinc Salts in an Acidified Medium

FIRST AID MEASURES

SKIN:  IMMEDIATELY REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN WITH RUNNING WATER FOR AT LEAST 15 MINUTES. WASH SKIN WITH SOAP AND WATER. LAUNDER CLOTHING BEFORE REUSE.

EYES:  FLUSH CONTINUOUSLY WITH WATER FOR 15 MINUTES. FORCIBLY HOLD EYELIDS APART TO ENSURE IRRIGATION OF ALL EYE TISSUE. SEEK PROMPT MEDICAL ATTENTION.

INHALATION:  REMOVE TO FRESH AIR. APPLY ARTIFICIAL RESPIRATION OR ADMINISTER OXYGEN IF NECESSARY. SEEK PROMPT MEDICAL ATTENTION IF SYMPTOMS PERSIST.

INGESTION:  NEVER GIVE ANYTHING BY MOUTH IF VICTIM IS RAPIDLY LOSING CONSCIOUSNESS OR IS UNCONCIOUS OR CONVULSING. HAVE VICTIM RINSE MOUTH THROUGHLY WITH WATER.  IF CONSIOUS GIVE 100 ML OF WATER AND INDUCE VOMITING. SEEK MEDICAL ATTENTION IMMEDIATELY.


PRECAUTIONARY MEASURES

AVOID CONTACT WITH SKIN AND EYES.  AVOID BREATHING VAPOURS.

WEAR ADEQUATE PROTECTIVE CLOTHES


PRECAUTIONARY EQUIPMENT

GLOVES/TYPE: WEAR IMPERVIOUS GLOVES IN NEOPRENE OR RUBBER.

RESPIRATOR TYPE: WHERE VAPOURS OR MIST ARE PRESENT, USE AN APPROVED NIOSH/MHSA APPROVED RESPIRATOR FOR THE INDICATED COMPONENTS, OR USE AN APPROVED AIR SUPPLIED RESPIRATOR. A RESPIRATOR WITH DUST/MIST FILTER IS REQUIRED UNDER DUSTY OR MISTY CONDITIONS.

EYE/TYPE: CHEMICAL GOOGLES.

FOOTWEAR/TYPE: SAFETY BOOTS.


RISK PHRASES

WARNING! THIS PRODUCT IS CONSIDERED TOXIC. IS A SKIN AND EYE IRRITANT. USE PROPER PROTECTIVE MEASURES.  FOR MORE INFORMATION SEE MSDS.


FONDEL Chemicals Ltd.

9688 Regional Rd. 25, Milton, Ontario, CANADA L9T 2X7

Tel: 905/878-8432  Fax: 905/878-7262  E-mail: Canada@fondel.com

Emergency Spill Line: North America 24/7 – NEWALTA- (800) 567-7455

PRODUCT OF CANADA

50 LBS.    25 KG.









Copper Mate 
acidified cupric and zinc sulfate  powder, for solution










Product Information
Product TypeOTC ANIMAL DRUGNDC Product Code (Source)51044-401
Route of AdministrationTOPICALDEA Schedule    














Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Cupric Sulfate (Cupric Cation)Cupric Cation0.25 kg  in 1.6 kg
ZINC SULFATE MONOHYDRATE (Zinc Cation)Zinc Cation0.1 kg  in 1.6 kg
CITRIC ACID MONOHYDRATE (CARBON DIOXIDE)CARBON DIOXIDE0.05 kg  in 1.6 kg





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
151044-401-2525 kg In 1 BAGNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other12/15/2010


Labeler - Fondel Chemical Ltd. (201786790)

Registrant - Fondel Chemical Ltd. (201786790)









Establishment
NameAddressID/FEIOperations
Fondel Chemical Ltd.201786790manufacture, label
Revised: 12/2010Fondel Chemical Ltd.



Wednesday, 29 August 2012

Phena-S Liquid


Pronunciation: klor-fen-IHR-ah-meen/fen-ill-EF-rin/peer-IL-a-meen
Generic Name: Chlorpheniramine/Phenylephrine/Pyrilamine
Brand Name: Phena-S


Phena-S Liquid is used for:

Relieving symptoms of sinus congestion, pressure, runny nose, and sneezing due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.


Phena-S Liquid is an antihistamine and decongestant combination. The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The decongestant promotes sinus and nasal drainage, which relieves congestion and pressure.


Do NOT use Phena-S Liquid if:


  • you are allergic to any ingredient in Phena-S Liquid

  • you have severe high blood pressure, severe heart blood vessel disease, rapid heartbeat, or severe heart problems

  • you take sodium oxybate (GHB) or if you have taken furazolidone or a monoamine oxidase (MAO) inhibitor (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.



Before using Phena-S Liquid:


Some medical conditions may interact with Phena-S Liquid. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, plan to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a fast, slow, or irregular heartbeat

  • if you have a history of asthma; lung problems (eg, emphysema); adrenal gland problems (eg, adrenal gland tumor); heart problems; high blood pressure; diabetes; heart blood vessel problems; stroke; glaucoma; a blockage of your bladder, stomach, or intestines; ulcers; trouble urinating; an enlarged prostate; seizures; or an overactive thyroid

Some MEDICINES MAY INTERACT with Phena-S Liquid. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Beta-blockers (eg, propranolol), COMT inhibitors (eg, tolcapone), furazolidone, indomethacin, MAO inhibitors (eg, phenelzine), sodium oxybate (GHB), or tricyclic antidepressants (eg, amitriptyline) because side effects of Phena-S Liquid may be increased

  • Digoxin or droxidopa because risk of irregular heartbeat or heart attack may be increased

  • Bromocriptine or hydantoins (eg, phenytoin) because side effects may be increased by Phena-S Liquid

  • Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because effectiveness may be decreased by Phena-S Liquid

This may not be a complete list of all interactions that may occur. Ask your health care provider if Phena-S Liquid may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Phena-S Liquid:


Use Phena-S Liquid as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Phena-S Liquid may be taken with or without food.

  • Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.

  • If you miss a dose of Phena-S Liquid, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Phena-S Liquid.



Important safety information:


  • Phena-S Liquid may cause dizziness, drowsiness, or blurred vision. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Phena-S Liquid. Using Phena-S Liquid alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks.

  • Do not take diet or appetite control medicines while you are taking Phena-S Liquid without checking with your doctor.

  • Phena-S Liquid contains phenylephrine. Before you begin taking any new prescription or nonprescription medicine, read the ingredients to see if it also contains phenylephrine. If it does or if you are uncertain, contact your doctor or pharmacist.

  • Do NOT exceed the recommended dose or use/take Phena-S Liquid for longer than prescribed without checking with your doctor.

  • If your symptoms do not improve within 5 to 7 days or if they become worse, check with your doctor.

  • Phena-S Liquid may cause increased sensitivity to the sun. Avoid exposure to the sun, sunlamps, or tanning booths until you know how you react to Phena-S Liquid. Use a sunscreen or protective clothing if you must be outside for a prolonged period.

  • If you are scheduled for allergy skin testing, do not take Phena-S Liquid for several days before the test because it may decrease your response to the skin tests.

  • Before you have any medical or dental treatments, emergency care, or surgery, tell the doctor or dentist that you are using Phena-S Liquid.

  • Use Phena-S Liquid with caution in the ELDERLY because they may be more sensitive to its effects.

  • Caution is advised when using Phena-S Liquid in CHILDREN because they may be more sensitive to its effects.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant while taking Phena-S Liquid, discuss with your doctor the benefits and risks of using Phena-S Liquid during pregnancy. It is unknown if Phena-S Liquid is excreted in breast milk. Do not breast-feed while taking Phena-S Liquid.


Possible side effects of Phena-S Liquid:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Constipation; diarrhea; dizziness; drowsiness; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor; trouble sleeping; vision changes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Phena-S side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.


Proper storage of Phena-S Liquid:

Store Phena-S Liquid at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Phena-S Liquid out of the reach of children and away from pets.


General information:


  • If you have any questions about Phena-S Liquid, please talk with your doctor, pharmacist, or other health care provider.

  • Phena-S Liquid is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Phena-S Liquid. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Phena-S resources


  • Phena-S Side Effects (in more detail)
  • Phena-S Use in Pregnancy & Breastfeeding
  • Phena-S Drug Interactions
  • Phena-S Support Group
  • 0 Reviews for Phena-S - Add your own review/rating


Compare Phena-S with other medications


  • Cold Symptoms
  • Hay Fever

Sunday, 26 August 2012

Tolazamide


Class: Sulfonylureas
ATC Class: A10BB05
VA Class: HS502
Chemical Name: 1-(Hexahydro-1-H-azepin-1-yl)-3-(p)-tolylsulfonyl) urea
CAS Number: 1156-19-0

Introduction

Antidiabetic agent; sulfonylurea.a b


Uses for Tolazamide


Diabetes Mellitus


Monotherapy as an adjunct to diet and exercise for the management of type 2 (noninsulin-dependent) diabetes mellitus in patients whose hyperglycemia cannot be controlled by diet and exercise alone.a b


Second-line therapy in combination with one or more other oral antidiabetic agents or insulin as an adjunct to diet and exercise in patients with type 2 diabetes mellitus who do not achieve adequate glycemic control with diet, exercise, and oral antidiabetic agent monotherapy. 136 146 147 148 149 150 166 167 169 170 171 172 173 174 175 176


Alternative therapy in some type 2 diabetic patients being treated with insulin or other antidiabetic agent(s) or unresponsive to other sulfonylureas.a Useful in combination with insulin to improve glycemic control and/or decrease insulin dosage in some type 2 diabetic patients.136 146 147 151 152 154 155 156 157 158 159


Not effective as sole therapy for patients with type 1 diabetes mellitus101 103 106 132 b or diabetic acidosis, ketosis, or coma; insulin is necessary.101 102 106 a b (See Contraindications under Cautions.)


Not routinely recommended in hospitalized patients with diabetes mellitus.119 Long duration of action precludes rapid dosage adjustments.119 132 Increased risk of hypoglycemia in hospitalized diabetic patients with irregular eating patterns.119


Tolazamide Dosage and Administration


General



  • Adjust dosage according to severity of disease, tolerance, and blood glucose determinations.b




  • Monitor regularly (e.g., blood glucose concentrations) to determine minimum effective dosage and to detect primary or secondary failure.119 a b




  • Monitor glycosylated hemoglobin (HbA1c) to determine patient’s continued response to therapy.119




  • During transfer from insulin therapy, patients should test their blood glucose concentrations ≥3 times daily.a b



Administration


Oral Administration


Administer orally as a single dose with breakfast or first main meal; for dosages >500 mg daily, administer in 2 divided doses.a b


Dosage


Adults


Type 2 Diabetes Mellitus

Initial Dosage

Oral

Initially, 100–250 mg daily.a b


Manufacturer suggests that, if the fasting blood glucose is <200 mg/dL, initially, 100 mg daily; if fasting blood glucose >200 mg/dL, initially, 250 mg daily.a b


Initial Dosage in Patients Transferred from Other Oral Antidiabetic Agents

May discontinue most other oral antidiabetic agents abruptly.a b


Oral

Acetohexamide: Initially, 100 mg daily for each 250 mg daily of acetohexamide.a b


Chlorpropamide: Administer the nearest equivalent total daily dosage; however, an exaggerated hypoglycemic response may occur in some patients during the transition because of the prolonged elimination half-life of chlorpropamide.a b Monitor closely for hypoglycemia during the initial 1- to 2-week transition period.a b


Tolbutamide: Tolbutamide dosages ≤1 g daily, initially 100 mg daily.b Tolbutamide dosage >1 g daily, initially, 250 mg daily.a b


Initial Dosage in Patients Transferred from Insulin

Oral

Insulin requirements <20 units daily: Initially, 100 mg daily.a b May abruptly discontinue insulin.a


Insulin requirements 20–40 units of insulin daily: Initially, 250 mg daily.a b May abruptly discontinue insulin.a


Insulin requirements >40 units daily: Initially, 250 mg daily; reduce daily insulin dosage by 50%.a b Subsequently, adjust insulin dosage according to therapeutic response.a b


Titration and Maintenance Dosage

Oral

Titrate dosage according to patient's response, using lowest possible effective dosage.a b Adjust dosage in increments or decrements of 100–250 mg daily at weekly intervals.a b


Usual maintenance dosage is 100 mg to 1 g daily (average 250–500 mg daily).a b Patients not responding to 1 g daily are unlikely to respond to higher dosages.a b


Prescribing Limits


Adults


Type 2 Diabetes Mellitus

Oral

Maximum 1 g daily.a b


Special Populations


Hepatic Impairment


Use conservative initial and maintenance dosages to avoid hypoglycemia.a b


Renal Impairment


Use conservative initial and maintenance dosages to avoid hypoglycemia.a b


Geriatric Patients


Initially, 100 mg daily.a b May increase dosage by 50–125 mg daily at weekly intervals.a Use conservative initial and maintenance dosages to avoid hypoglycemia.a b


Debilitated or Malnourished Patients


Initially, 100 mg daily.a b May increase dosage by 50–125 mg daily at weekly intervals.a Use conservative initial and maintenance dosages to avoid hypoglycemia.a b


Cautions for Tolazamide


Contraindications



  • Known hypersensitivity to tolazamide.b




  • Monotherapy for type 1 diabetes mellitus.a b




  • Diabetic ketoacidosis, with or without coma.a b




  • Acute complications (e.g., major surgery, severe infection, or severe trauma).a




  • Uremia.a



Warnings/Precautions


Warnings


Cardiovascular Effects

Increased cardiovascular mortality reported with certain other antidiabetic agents (i.e., tolbutamide, phenformin).106 108 109 112 125 129 130 131 b However, the American Diabetes Association (ADA) considers the benefits of intensive glycemic control with insulin or sulfonylureas to outweigh the risks overall.109 119 125


Sensitivity Reactions


Dermatologic Reactions

Possible allergic skin reaction (e.g., pruritus, erythema, urticaria, rash, morbilliform or maculopapular eruptions).a b May be transient; discontinue the drug if reaction persists.b


Photosensitivity Reactions

Rarely, photosensitivity reactions reported.a b


General Precautions


Hypoglycemia

Possibly severe hypoglycemia reported, especially in debilitated, malnourished, or geriatric patients and patients with adrenal, pituitary, hepatic, or renal insufficiency.a b Strenuous exercise, alcohol ingestion, insufficient caloric intake, or use in combination with other antidiabetic agents may increase risk.a b


Hypoglycemia may be difficult to recognize in geriatric patients and in those receiving β-adrenergic blocking agents.b (See Specific Drugs under Interactions.)


Increased risk of hypoglycemia in patients with irregular eating patterns.119


Appropriate patient selection and careful dosing and instructions are important to avoid tolazamide-induced hypoglycemia.a b


If hypoglycemia occurs, immediately reevaluate patient and adjust insulin or tolazamide dosage.a Monitor patient for ≥24–48 hours; may require hospitalization and IV dextrose.b


Loss of Glycemic Control

Possible loss of glycemic control during periods of stress (e.g., fever, trauma, infection, surgery).a b May require use of insulin and/or temporary discontinuance of tolazamide.a b


Efficacy of therapy may decrease over time (secondary failure); evaluate patients at regular intervals.a b


Assess patients for adequate adjustment of dose and adherence to diet before attributing inadequate response to secondary failure.b


Manufacturer recommends discontinuance of tolazamide if satisfactory glycemic control no longer is achieved.b ADA and other clinicians recommend addition of other oral antidiabetic agents or insulin.124 147 179 180 181 182 183 186 188 (See Diabetes Mellitus under Uses.)


Hepatic Effects

Cholestatic jaundice and alterations in liver function test results (e.g., bilirubin, cholesterol, AST, ALT) reported.a b If cholestatic jaundice occurs, discontinue the drug.b


Use with caution in patients with a history of hepatic porphyria; sulfonylureas may exacerbate this condition.a b


Specific Populations


Pregnancy

Category C.b


Many experts recommend the use of insulin during pregnancy.b


Not recommended for use during pregnancy by manufacturer.b Prolonged (4–10 days), severe hypoglycemia reported in some neonates born to women receiving a sulfonylurea at delivery; more frequent with long-acting sulfonylureas.b If used during pregnancy, discontinue ≥2 weeks before the expected delivery date to minimize the risk of neonatal hypoglycemia.b


Lactation

Not known whether tolazamide is distributed into human milk.b Some sulfonylurea drugs are distributed into human milk.b Discontinue nursing or the drug.b


If drug is discontinued and diet alone is inadequate for glycemic control, consider insulin.b


Pediatric Use

Safety and efficacy not established.b


Geriatric Use

Increased risk of hypoglycemia;a b hypoglycemia may be difficult to recognize.b


Possible increased risk of hypoglycemia due to age-related decreases in renal function.b Renal function monitoring recommended; select dosage with caution.a b


Hepatic Impairment

Increased risk of hypoglycemia; conservative dosing recommended.a b


Renal Impairment

Increased risk of hypoglycemia; conservative dosing recommended.b (See Renal Impairment under Special Populations in Dosage and Administration.)


Common Adverse Effects


Nausea,a b epigastric fullness,b heartburn,b vomiting,a anorexia,a intestinal gas,a diarrhea,a constipation,a cramps.a


Interactions for Tolazamide


Protein-bound Drugs


Potential pharmacokinetic interaction (increased hypoglycemic effect).b (See Specific Drugs under Interactions.)


Close observation recommended when initiating or discontinuing concomitant therapy with a highly protein-bound drug.b


Specific Drugs








































































Drug



Interaction



Comments



Alcohol



Possible disulfiram-like reactionsa


May predispose patients to the development of hypoglycemiab



Anticoagulants, oral



Possible potentiation of hypoglycemic effectsb



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Antifungals, oral (i.e., fluconazole, miconazole)



Increased plasma concentrations of the oral antidiabetic agent and/or possible hypoglycemia167 b



Not known whether interaction occurs with IV, topical, or vaginal miconazoleb


Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



β-Adrenergic blocking agents



Possible potentiation of hypoglycemic effectsb


Signs of hypoglycemia may be masked by β-adrenergic blocking agentsb



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Calcium-channel blocking agents



Potential for decreased hypoglycemic effectb



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Chloramphenicol



Possible potentiation of hypoglycemic effectsb



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Contraceptives, oral



Potential for decreased hypoglycemic effectb



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Corticosteroids



Potential for decreased hypoglycemic effectb



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Diuretics



Potential for decreased hypoglycemic effecta b


May cause temporary loss of diabetic control or secondary failurea



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinueda b



Estrogens



Potential for decreased hypoglycemic effectb



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Insulin



Possible potentiation of hypoglycemic effectsa



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Isoniazid



Potential for decreased hypoglycemic effectb



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



MAO inhibitors



Possible potentiation of hypoglycemic effectsa b



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Niacin



Potential for decreased hypoglycemic effectb



Observe carefully for hypoglycemia or loss of glycemic control or when concurrent therapy is initiated or discontinuedb



NSAIAs



Possible potentiation of hypoglycemic effectsb



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Phenothiazines



Potential for decreased hypoglycemic effectb



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Phenytoin



Potential for decreased hypoglycemic effectb



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Probenecid



Possible potentiation of hypoglycemic effectsa b



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Salicylates



Possible potentiation of hypoglycemic effectsa b



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Sulfonamides



Possible potentiation of hypoglycemic effectsa b



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Sympathomimetic agents



Potential for decreased hypoglycemic effectb



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb



Thyroid agents



Potential for decreased hypoglycemic effectb



Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb


Tolazamide Pharmacokinetics


Absorption


Bioavailability


Rapidly and well absorbed following oral administration.b Peak serum concentrations attained at 3–4 hours.b


Onset


Following a single 500 mg dose in nondiabetic, fasting adults, hypoglycemic effect occurs within 20 minutes; peak hypoglycemic effect occurs at 1–4 hours.a b


Following a single 500 mg dose in fasting diabetics, peak hypoglycemic effect occurs at 4–6 hours.b


In nonfasting diabetics, onset of hypoglycemic effect occurs within 4–6 hours.a b


Duration


In nondiabetic, fasting adults, pharmacologic effects persist for at least 20 hours.a b


In nonfasting diabetics, hypoglycemic activity persists for about 10 hours; blood glucose concentrations begin to increase at 14–16 hours following a single dose.a b


Distribution


Extent


Distributed into extracellular fluids; distribution not fully characterized.a


Not known whether tolazamide is distributed into milk.b


Elimination


Metabolism


Metabolized to active and inactive metabolites, probably in the liver.a b


Elimination Route


Excreted principally in urine (85%) principally as metabolites and in feces (7%); small amounts excreted in urine unchanged.a b


Half-life


Approximately 7 hours.a b


Stability


Storage


Oral


Tablets

Tight, light-resistant containers at 20–25°C.a b Protect from light.b


ActionsActions



  • Mechanism of long-term hypoglycemic action of sulfonylurea antidiabetic agents has not been clearly established.b Appears to lower blood glucose concentration principally by stimulating the secretion of endogenous insulin from the beta cells of the pancreas.a b




  • Ineffective in the absence of functioning beta cells.a




  • Lowers blood glucose concentration in diabetic and nondiabetic individuals.a b




  • During prolonged administration, extrapancreatic effects (e.g., enhanced peripheral sensitivity to insulin, reduction of basal hepatic glucose production) may contribute to the hypoglycemic action.a b




  • A gradual decline in the insulin secretory response to drug may occur; however, blood glucose lowering effect persists.b




  • May produce a mild diuresis by enhancement of renal free water clearance.b



Advice to Patients



  • Importance of informing patients of potential risks and advantages of tolazamide therapy and of alternative forms of treatment.b




  • Importance of regular monitoring of blood glucose (preferable self-monitoring) and of HbA1c.b




  • According to manufacturer, patients should test their urine for glucose and acetone ≥3 times daily during insulin withdrawal.b Report abnormal results to clinician for appropriate adjustments in therapy.b




  • Importance of hygiene and avoidance of infection.a




  • Advise patients about nature of diabetes mellitus, prevention and detection of complications, and importance of glycemic control.a




  • Risks of hypoglycemia.a b Importance of patients and responsible family members understanding symptoms and treatment of hypoglycemic reactions and identifying conditions that predispose to development of such reactions.a b




  • Importance of understanding primary and secondary failure to therapy.b




  • Importance of adherence to diet and exercise regimen.a b




  • Risk of photosensitivity reactions.a b




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.b




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.b Inform patients that tolazamide is not recommended during pregnancy.b




  • Importance of informing patients of other important precautionary information.b (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name


















Tolazamide

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets



250 mg*



Tolazamide Tablets (scored)



500 mg*



Tolazamide Tablets (scored)


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


TOLAZamide 100MG Tablets (IVAX PHARMACEUTICALS INC.): 60/$26.99 or 180/$68.97


TOLAZamide 250MG Tablets (MYLAN): 60/$35.99 or 180/$96.97


TOLAZamide 500MG Tablets (MYLAN): 30/$45.99 or 90/$109.96



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions May 2009. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References



101. The Upjohn Company. Micronase (glyburide) prescribing information. Kalamazoo, MI; 1988 May.



102. Hoechst-Roussel Pharmaceuticals Inc. Diaβeta (glyburide) prescribing information. Somerville, NJ; 1987 Dec.



103. Anon. Glibenclamide: a review. Drugs. 1971; 1:116-40. [PubMed 5004340]



104. DeFronzo RA, Ferrannini E, Koivisto V. New concepts in the pathogenesis and treatment of noninsulin-dependent diabetes mellitus. Am J Med. 1983; 74(Suppl 1A):52-81. [IDIS 164138] [PubMed 6337486]



105. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979; 28:1039-57. [PubMed 510803]



106. Koda-Kimble MA. Diabetes mellitus. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs. 5th ed. Vancouver, WA: Applied Therapeutics, Inc.; 1992:72–1-53.



107. Skyler JS. Non-insulin-dependent diabetes mellitus: a clinical strategy. Diabetes Care. 1984; 7(Suppl 1):118-29. [PubMed 6376024]



108. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53. [IDIS 413216] [PubMed 9742976]



109. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 1999; 22(Suppl 1):27-31. [IDIS 437591] [PubMed 10333899]



110. Matthews DR, Cull CA, Stratton RR et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over 6 years. Diabet Med. 1998; 15:297-303. [PubMed 9585394]



111. Genuth P. United Kingdom prospective diabetes study results are in. J Fam Pract. 1998; 47:(Suppl 5):S27.



112. Bretzel RG, Voit K, Schatz H et al. The United Kingdom Prospective Diabetes Study (UKPDS): implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 1998; 106:369-72. [PubMed 9831300]



113. Schmitt JK, Moore JR. Hypertension secondary to chlorpropamide with amelioration by changing to insulin. Am J Hypertens. 1993; 6:317-9. [PubMed 8507452]



114. Genuth S, Brownless MA, Kuller LH et al. Consensus development conference on insulin resistance: Novermber 5-6 1997. Diabetes Care. 1998; 21:310-4. [IDIS 400179] [PubMed 9540000]



115. Henry RR. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996; 124:97-103. [IDIS 358776] [PubMed 8554221]



116. Lebovitz HE. Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care. 1994; 17:1542-4. [IDIS 340102] [PubMed 7882832]



117. Nathan DM. Some answers, more controversy, from UKDS. Lancet. 1998; 352:832-3. [IDIS 413214] [PubMed 9742972]



118. Reviewers’ comments (personal observations) on metformin.



119. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2006; 29(Suppl 1):S4-42.



120. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86. [IDIS 320201] [PubMed 8366922]



121. Klein R, Klein BEK, Moss SE et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988; 260:2864-71. [PubMed 3184351]



122. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care. 1996; 19:50-2S.



123. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus; a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28:103-17. [PubMed 7587918]



124. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metfromin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-65. [IDIS 413217] [PubMed 9742977]



125. American Diabetes Association. The United Kingdom Prospective Diabetes Study (UKPDS) for type 2 diabetes: what you need to know about the results of a long-term study. Washington, DC; September 15, 1998. From American Diabetes Association web site.



126. Davis TM. United Kingdom Prospective Diabetes Study: the end of the beginning? Med J Aust. 1998; 169:511-2.



127. Watkins PJ. UKPDS: a message of hope and a need for change. Diabet Med. 1998; 15:895-6. [PubMed 9827842]



128. Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirements for multiple therapies (UKPDS 49). JAMA. 1999; 281:2005-12. [IDIS 425712] [PubMed 10359389]



129. Scientific Advisory Panel of the Executive Committee, American Diabetes Association. Policy statement: the UGDP controversy. Diabetes. 1979; 28:168-70.



130. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. Drugs. 1981; 22:295-320. [IDIS 143257] [PubMed 7030708]



131. Food and Drug Administration. Labeling for oral hypoglycemic drugs of the sulfonylurea class. [Docket No. 75N-0062] Fed Regist. 1984; 49:14303-31.



132. Pharmacia & Upjohn Company. Tolinase (tolazamide) tablets prescribing information. Kalamazoo, MI; 2000 Jan.



133. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2000; 23(Suppl 1):S4-19.



134. American Diabetes Association. Type 2 diabetes in children and adolescents. Pediatrics. 2000; 105:671-80. [IDIS 443594] [PubMed 10699131]



135. American Diabetes Association. Office guide to diagnosis and classification of diabetes mellitus and other categories of glucose intolerance. Diabetes Care. 1995; 18(Suppl 1):4.



136. Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet. 1994; 343:95-100. [IDIS 324190] [PubMed 7903785]



137. Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124(1 Part 2):104-9.



138. DeFronzo RA. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988; 37:667-87. [PubMed 3289989]



139. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996; 334:777-83. [PubMed 8592553]



140. Swislocki A. Insulin resistance and hypertension. Am J Med Sci. 1990; 300:104-15. [IDIS 272104] [PubMed 2206054]



141. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317:703-13. [IDIS 412064] [PubMed 9732337]



142. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes mellitus: UKPDS 39. BMJ. 1998; 317:713-20. [IDIS 412065] [PubMed 9732338]



143. Haffner SM, Hanefeld M, Fischer S et al. Glibenclamide, but not acarbose, increase leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care. 1997; 20: 1430-4. [IDIS 393377] [PubMed 9283792]



144. Shi H, Moustaid-Moussa N, Wilkison WO et al. Role of the sulfonylurea receptor in regulating human adipocyte metabolism. FASEB J. 1999; 13:1833-8. [PubMed 10506587]



145. Cheskin LJ, Bartlett SJ, Zayas R et al. Prescription medications: a modifiable contributor to obesity. South Med J. 1999; 92:898-904. [IDIS 435069] [PubMed 10498166]



146. Chow CC, Sorensen JP, Tsang LWW et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care. 1995; 18:307-14. [IDIS 346283] [PubMed 7555472]



147. Zimmerman B, Espenshade J, Fujimoto W et al. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care. 1996; 19:1510-18.



148. Expert Committee of the Canadian Diabetes Advisory Board. Clinical practice guidelines for treatment of diabetes mellitus. Can Med Assoc J. 1992; 147:697-712.



149. Raskin P. Combination therapy in NIDDM N Engl J Med. 1992; 327:1453-4. Editorial.



150. Pugh JA, Ramirez G, Wagner ML et al. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care. 1992; 15:953-9. [PubMed 1387073]



151. Landstedt-Hallin L, Bolinder J, Adamson U et al. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care. 1995; 18:1183-6. [IDIS 351422] [PubMed 7587856]



152. Trischitta V, Italia S, Mazzarino S et al. Comparison of combined therapies in treatment of secon dary failure to glyburide. Diabetes Care. 1992; 15:539-42. [PubMed 1499473]



153. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Safety. 1994; 11:223-41. [PubMed 7848543]



154. Buse J. Combining insulin and oral agents. Am J Med. 2000; 108(Suppl 6A):23S-32S. [IDIS 446200] [PubMed 10764847]



155. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med. 1996; 156:259-64. [IDIS 363130] [PubMed 8572835]



156. Florence JA, Yeager BF. Treatment of type 2 diabetes mellitus. Am Fam Physician. 1999; 59:2835-44. [IDIS 428714] [PubMed 10348076]



157. Yki-Jarvinen H, Dressler A, Ziemen M et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime HPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000; 23:1130-6 (IDIS 451244) [IDIS 451244] [PubMed 10937510]



158. Bastyr EJ, Johnson ME, Trautman ME et al. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther. 1999; 21:1703-4. [IDIS 438022] [PubMed 10566566]



159. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999; 131:281-303. [IDIS 430576] [PubMed 10454950]



160. Lebovitz HE. Clinical utility of oral hypoglycemic agents in the management of patients with noninsulin-dependent diabetes mellitus. Am J Med. 1983; 75(Suppl. 5B):94-9.



161. Anon. Diabetes mellitus. NIH Cons Dev Conf Statement. 1986; 6:1-7.



162. Blake GH. Control of type II diabetes: reaping the rewards of exercise and weight loss. Postgrad Med. 1992; 92:129-32. [PubMed 1437899]



163. Kerr CP. Improving outcomes in diabetes: a review of the outpatient care of NIDDM patients. J Fam Pract. 1995; 40:63-75. [PubMed 7807040]



164. Bailey C, Turner R. Metformin. N Engl J Med. 1996; 334:574-9. [IDIS 360526] [PubMed 8569826]



165. Turner R, Cull C, Holman R et al. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996; 124(1 Pt 2):136-45. [IDIS 358782] [PubMed 8554206]



166. Bristol-Myers-Squibb Company. Glucovance(glyburide and metformin hydrochloride) tablets prescribing information. Princeton, NJ; 2002 Oct.



167. Pfizer Inc. Glucotrol XL(glipizide) extended release tablets prescribing information. New York, NY; 2001 Apr.



168. Pfizer. Diflucan (fluconazole) tablets, for oral suspension, and injection prescribing information. New York, NY; 1998 Jun.



169. Wolffenbuttel BHR, Gomist R, Squatrito S et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med. 2000; 17:40-7. [PubMed 10691158]



170. Takeda Pharmaceuticals America. Actos (pioglitazone hydrochloride) tablets prescribing information. Lincolnshire, IL; 2002 July.



171. SmithKline Beecham. Avandia (rosiglitazone maleate) tablets prescribing information. Philadelphia, PA; 2002 May



172. Kipnes MS, Krosnick a, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001; 111:10-7. [IDIS 467740] [PubMed 11448655]



173. Chiasson J, Josse R, Hunt J et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1994; 121:929-935.



174. Coniff RF, Shapiro JA, Seaton TB et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995; 98:443-51. [IDIS 348267] [PubMed 7733122]



175. Calle-Pascual AL, Garcia-Honduvilla J, Martin-Alvarez PJ et al. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Diabetes Metab. 1995; 21:256-60.



176. Klein W. S